Truly Technologies develops biospecimen processing technologies for diagnostic, therapeutic and life science research applications.
Truly Technologies has raised $273K in total funding. The most recent round was Grant. The last funding was announced in May 2023.
Truly Technologies's investors include National Institute of Allergy and Infectious Diseases, CoMotion, University of Washington.
Truly Technologies is headquartered in Seattle, United States.
Truly Technologies develops biospecimen processing technologies for diagnostic, therapeutic and life science research applications.
Truly Technologies is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Truly Technologies — Funding & Investors." VCBacked, May 1, 2023, https://www.vcbacked.co/company/truly-technologies. Accessed August 14, 2026.
VCBacked. (2023). Truly Technologies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/truly-technologies
{{cite web |title=Truly Technologies — Funding & Investors |url=https://www.vcbacked.co/company/truly-technologies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated